Keong Chong

Keong Chong

Auto-generated profile, based on publicly available information

Keong Chong

Department of Internal Medicine Min‐Sheng General Hospital Taoyuan Taiwan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2024 in The Kaohsiung Journal of Medical Sciences
Verified
Journal Article
Open access
KCKeong Chong
Keong Chong
JCJack Keng‐Jui Chang
Jack Keng‐Jui Chang
莊C莊立民 Lee-Ming Chuang
莊立民 Lee-Ming Chuang
Several recent advances provide multiple health benefits to individuals with type 2 diabetes mellitus (T2DM). Pharmacological therapy is governed by person‐centered factors, including comorbidities and treatment goals. Adults with T2DM who have an established/high risk of atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, require a treatment regimen that includes agents that are proven to reduce cardiorenal risk. Weight management plays a key role in reducing glucose for patients with T2DM. A glucose‐reduction treatment regimen must consider weight management. Sodium glucose co‐transporter 2 (SGLT2) inhibitors reduce the risk of heart failure, cardiovascular and renal events. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists allow better control of glycemia, promote weight loss and reduce the risk of cardiovascular events. Newer Glucose‐dependent insulinotropic polypeptide (GIP) and GLP‐1 dual agonist, which activate GIP and GLP‐1 receptors improve glycemic control and promote greater weight loss than GLP‐1 receptor agonists. Several novel drugs are in the clinical development phase. This review pertains to recent advances in pharmacological management of type 2 diabetes.

18 July 2020 in Obesity Surgery
Verified
Journal Article
Open access
PDF file
YCYi-Cheng Chang
Yi-Cheng Chang
SCSeh-Huang Chao
Seh-Huang Chao
CCChing-Chu Chen
Ching-Chu Chen
KSKong-Han Ser
Kong-Han Ser
KCKeong Chong
Keong Chong
WLWei Jei Lee
Wei Jei Lee
Background: Bariatric surgery has been shown to improve glycemic control in patients with type 2 diabetes. However, less is known whether it can also reduce diabetic renal, neurological, and ophthalmic complications. Methods: This prospective multicenter cohort study compared renal, ophthalmic, and neurological complications between 49 patients with obesity/overweight receiving bariatric surgery and 338 patients receiving standard medical treatment after follow-up for 2 years. Patients received neurological examinations including toe tuning fork vibration test, ankle tendon reflex test, 10-g monofilament test, and ophthalmic examinations including visual acuity measurement and fundus examinations. Multiple regressions, propensity score weighting, and matching were employed to adjust for baseline differences. Results: After 2 years of follow-up, patients with type 2 diabetes receiving bariatric surgery had greater reduction in BMI, HbA1c, and urine albumin–creatinine ratio, greater improvement in estimated glomerular filtration rate, and greater increase in tuning fork test score of right and left toes compared with the medical group. However, there is no improvement in 10 g-monofilament test, visual acuity, diabetic non-proliferative retinopathy, and proliferative retinopathy. Similar results were obtained using multiple regression adjustment, propensity-score weighting, or comparing age-, sex-, and BMI-matched subjects. Conclusions: After 2-year follow-up, patients with obesity/overweight and type 2 diabetes receiving bariatric surgery have increased glomerular filtration rate, reduced albuminuria, and improved tuning folk vibration sensation.

14 March 2015 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
WLWei Jei Lee
Wei Jei Lee
MLMing-Hsien Lee
Ming-Hsien Lee
PYPo-Jui Yu
Po-Jui Yu
JWJih-Hua Wei
Jih-Hua Wei
KCKeong Chong
Keong Chong
Yi Chih LeeYi Chih Lee
Yi Chih Lee